116 related articles for article (PubMed ID: 38546086)
1. Curcumin Inhibits the PPARδ-p-Akt-GLUT1 Pathway and Ameliorates the Antiproliferative Effects of Doxorubicin in MDA-MB-231 Cells.
Thulasiraman P; Foret M; Pandit R; McAlister K
Asian Pac J Cancer Prev; 2024 Mar; 25(3):1035-1043. PubMed ID: 38546086
[TBL] [Abstract][Full Text] [Related]
2. Curcumin restores sensitivity to retinoic acid in triple negative breast cancer cells.
Thulasiraman P; McAndrews DJ; Mohiudddin IQ
BMC Cancer; 2014 Sep; 14():724. PubMed ID: 25260874
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Glut1 by WZB117 sensitizes radioresistant breast cancer cells to irradiation.
Zhao F; Ming J; Zhou Y; Fan L
Cancer Chemother Pharmacol; 2016 May; 77(5):963-72. PubMed ID: 27011212
[TBL] [Abstract][Full Text] [Related]
4. Curcumin suppresses doxorubicin-induced epithelial-mesenchymal transition via the inhibition of TGF-β and PI3K/AKT signaling pathways in triple-negative breast cancer cells.
Chen WC; Lai YA; Lin YC; Ma JW; Huang LF; Yang NS; Ho CT; Kuo SC; Way TD
J Agric Food Chem; 2013 Dec; 61(48):11817-24. PubMed ID: 24236784
[TBL] [Abstract][Full Text] [Related]
5. Opposite regulation by PI3K/Akt and MAPK/ERK pathways of tissue factor expression, cell-associated procoagulant activity and invasiveness in MDA-MB-231 cells.
Hu C; Huang L; Gest C; Xi X; Janin A; Soria C; Li H; Lu H
J Hematol Oncol; 2012 Jul; 5():16. PubMed ID: 22534171
[TBL] [Abstract][Full Text] [Related]
6. Activation of peroxisome proliferator-activated receptor-β/δ (PPAR-β/δ) inhibits human breast cancer cell line tumorigenicity.
Yao PL; Morales JL; Zhu B; Kang BH; Gonzalez FJ; Peters JM
Mol Cancer Ther; 2014 Apr; 13(4):1008-17. PubMed ID: 24464939
[TBL] [Abstract][Full Text] [Related]
7. Enhancing chemosensitivity of wild-type and drug-resistant MDA-MB-231 triple-negative breast cancer cell line to doxorubicin by silencing of STAT 3, Notch-1, and β-catenin genes.
Alkaraki A; Alshaer W; Wehaibi S; Gharaibeh L; Abuarqoub D; Alqudah DA; Al-Azzawi H; Zureigat H; Souleiman M; Awidi A
Breast Cancer; 2020 Sep; 27(5):989-998. PubMed ID: 32328816
[TBL] [Abstract][Full Text] [Related]
8. Blockade of GLUT1 by WZB117 resensitizes breast cancer cells to adriamycin.
Chen Q; Meng YQ; Xu XF; Gu J
Anticancer Drugs; 2017 Sep; 28(8):880-887. PubMed ID: 28609310
[TBL] [Abstract][Full Text] [Related]
9. [Effects of Astragalus polysaccharide on proliferation and Akt phosphorylation of the basal-like breast cancer cell line].
Ye MN; Chen HF; Zhou RJ; Liao MJ
Zhong Xi Yi Jie He Xue Bao; 2011 Dec; 9(12):1339-46. PubMed ID: 22152773
[TBL] [Abstract][Full Text] [Related]
10. The differential susceptibilities of MCF-7 and MDA-MB-231 cells to the cytotoxic effects of curcumin are associated with the PI3K/Akt-SKP2-Cip/Kips pathway.
Jia T; Zhang L; Duan Y; Zhang M; Wang G; Zhang J; Zhao Z
Cancer Cell Int; 2014; 14(1):126. PubMed ID: 25530715
[TBL] [Abstract][Full Text] [Related]
11. ADAM17 promotes breast cancer cell malignant phenotype through EGFR-PI3K-AKT activation.
Zheng X; Jiang F; Katakowski M; Zhang ZG; Lu QE; Chopp M
Cancer Biol Ther; 2009 Jun; 8(11):1045-54. PubMed ID: 19395875
[TBL] [Abstract][Full Text] [Related]
12. CIP2A is a target of bortezomib in human triple negative breast cancer cells.
Tseng LM; Liu CY; Chang KC; Chu PY; Shiau CW; Chen KF
Breast Cancer Res; 2012 Apr; 14(2):R68. PubMed ID: 22537901
[TBL] [Abstract][Full Text] [Related]
13. Acyl-CoA synthetase-4 is implicated in drug resistance in breast cancer cell lines involving the regulation of energy-dependent transporter expression.
Orlando UD; Castillo AF; Medrano MAR; Solano AR; Maloberti PM; Podesta EJ
Biochem Pharmacol; 2019 Jan; 159():52-63. PubMed ID: 30414939
[TBL] [Abstract][Full Text] [Related]
14. Down-regulating GRP78 reverses pirarubicin resistance of triple negative breast cancer by miR-495-3p mimics and involves the p-AKT/mTOR pathway.
Liu M; Yang J; Lv W; Wang S; Du T; Zhang K; Wu Y; Feng X
Biosci Rep; 2022 Jan; 42(1):. PubMed ID: 34935899
[TBL] [Abstract][Full Text] [Related]
15. Andrographolide Exhibits Anticancer Activity against Breast Cancer Cells (MCF-7 and MDA-MB-231 Cells) through Suppressing Cell Proliferation and Inducing Cell Apoptosis via Inactivation of ER-α Receptor and PI3K/AKT/mTOR Signaling.
Tohkayomatee R; Reabroi S; Tungmunnithum D; Parichatikanond W; Pinthong D
Molecules; 2022 May; 27(11):. PubMed ID: 35684480
[TBL] [Abstract][Full Text] [Related]
16. Anti-metastasis activity of curcumin against breast cancer via the inhibition of stem cell-like properties and EMT.
Hu C; Li M; Guo T; Wang S; Huang W; Yang K; Liao Z; Wang J; Zhang F; Wang H
Phytomedicine; 2019 May; 58():152740. PubMed ID: 31005718
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of the miR-141/200c cluster promotes the migratory and invasive ability of triple-negative breast cancer cells through the activation of the FAK and PI3K/AKT signaling pathways by secreting VEGF-A.
Choi SK; Kim HS; Jin T; Hwang EH; Jung M; Moon WK
BMC Cancer; 2016 Aug; 16():570. PubMed ID: 27484639
[TBL] [Abstract][Full Text] [Related]
18. Lapatinib sensitizes quiescent MDA-MB-231 breast cancer cells to doxorubicin by inhibiting the expression of multidrug resistance-associated protein-1.
Kwon YS; Chun SY; Nam KS; Kim S
Oncol Rep; 2015 Aug; 34(2):884-90. PubMed ID: 26063481
[TBL] [Abstract][Full Text] [Related]
19. Curcumin inhibits the invasion and metastasis of triple negative breast cancer via Hedgehog/Gli1 signaling pathway.
Li M; Guo T; Lin J; Huang X; Ke Q; Wu Y; Fang C; Hu C
J Ethnopharmacol; 2022 Jan; 283():114689. PubMed ID: 34592340
[TBL] [Abstract][Full Text] [Related]
20. H-Ferritin Enriches the Curcumin Uptake and Improves the Therapeutic Efficacy in Triple Negative Breast Cancer Cells.
Pandolfi L; Bellini M; Vanna R; Morasso C; Zago A; Carcano S; Avvakumova S; Bertolini JA; Rizzuto MA; Colombo M; Prosperi D
Biomacromolecules; 2017 Oct; 18(10):3318-3330. PubMed ID: 28886247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
